Elizabeth Wang, MD
Dermatology · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 3 carriers
- Office
- 1
Offices
1 location · Golden State Dermatology Associates, Inc. · 118 clinicians in this group
Looking this up.
Plans that list them
13 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office at (650) 727-6008 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A164401 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$114,103
Medicare paid this office $114,103 for 411 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 146 | $22,158 | $107 |
| Short return visit (20+ min) | 224 | $21,164 | $75 |
| Destruction of skin growth, 1-14 growths | 109 | $15,655 | $110 |
| Biopsy of related skin growth, first growth | 132 | $12,605 | $79 |
| Destruction of precancer skin growth, 1 growth | 110 | $6,463 | $47 |
See all 13 services
| Return visit (30+ min) | 146 | $22,158 | $107 |
| Short return visit (20+ min) | 224 | $21,164 | $75 |
| Destruction of skin growth, 1-14 growths | 109 | $15,655 | $110 |
| Biopsy of related skin growth, first growth | 132 | $12,605 | $79 |
| Destruction of precancer skin growth, 1 growth | 110 | $6,463 | $47 |
| Biopsy of related skin growth, each additional growth | 66 | $5,654 | $49 |
| Short return visit | 74 | $4,015 | $46 |
| New patient visit (30+ min) | 40 | $3,235 | $81 |
| Destruction of precancer skin growth, 2-14 growths | 83 | $3,109 | $7 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 11 | $3,047 | $277 |
| New patient visit (45+ min) | 22 | $2,727 | $124 |
| Punch biopsy, first skin growth | 20 | $2,408 | $115 |
| New patient visit (15+ min) | 13 | $710 | $55 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 540 | More than 87% of doctors who do this |
| Removal or shaving of skin growth | 95 | More than 84% of doctors who do this |
| Skin biopsy | 198 | More than 85% of doctors who do this |
Who their Medicare patients are
411 Original Medicare patients in 2024. Average age 77 · Women 65% · Also on Medicaid 4% · Health risk score 0.82. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 53% · Coronary heart disease 19% · Cancer 15% · Diabetes 13% · Chronic kidney disease 13% · Depression 12% · Atrial fibrillation 11% · Heart failure 8% · COPD 5% · Dementia 4% · Stroke 4%.
The office billed $433,806, Medicare allowed $162,642 and paid $114,103; for 1,793 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 411 | 1,793 | 77 | 0.82 | $433,806 | $114,103 |
| 2023 | 411 | 1,515 | 76 | 0.75 | $384,668 | $108,215 |
| 2022 | 160 | 509 | 75 | 0.65 | $113,585 | $35,074 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 133 | $22,126 | $112 |
| Destruction of skin growth, 1-14 growths | 113 | $15,617 | $105 |
| Short return visit (20+ min) | 149 | $14,362 | $76 |
| New patient visit (30+ min) | 100 | $8,066 | $81 |
| New patient visit (45+ min) | 59 | $7,782 | $132 |
| Biopsy of related skin growth, first growth | 79 | $7,430 | $84 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 36 | $5,314 | $108 |
| Destruction of precancer skin growth, 1 growth | 80 | $4,701 | $47 |
| Biopsy of related skin growth, each additional growth | 38 | $3,119 | $49 |
| Long return visit (40+ min) | 15 | $3,060 | $161 |
| Destruction of precancer skin growth, 2-14 growths | 53 | $2,475 | $7 |
| Short return visit | 22 | $1,111 | $44 |
2022: 8 services
| Destruction of skin growth, 1-14 growths | 48 | $6,534 | $119 |
| Return visit (30+ min) | 37 | $6,401 | $114 |
| Short return visit (20+ min) | 49 | $4,585 | $83 |
| New patient visit (30+ min) | 50 | $4,489 | $90 |
| New patient visit (45+ min) | 30 | $4,198 | $140 |
| Destruction of precancer skin growth, 1 growth | 37 | $2,034 | $47 |
| Biopsy of related skin growth, first growth | 18 | $1,558 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $1,056 | $7 |
Drugs they prescribed that Part D paid
$119,593
Pharmacies billed $119,593 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 597) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
551 generic and 46 brand-name prescriptions · $119,593 in drug cost · 38 antibiotic prescriptions to 25 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 17 | $60,694 | $3,570 |
| Fluorouracil | 23 | $2,174 | $95 |
| Clobetasol Propionate | 49 | $2,099 | $43 |
| Ketoconazole | 74 | $1,101 | $15 |
| Dutasteride | 15 | $1,068 | $71 |
See all 17 drugs
| Dupixent | 17 | $60,694 | $3,570 |
| Fluorouracil | 23 | $2,174 | $95 |
| Clobetasol Propionate | 49 | $2,099 | $43 |
| Ketoconazole | 74 | $1,101 | $15 |
| Dutasteride | 15 | $1,068 | $71 |
| Tretinoin | 15 | $849 | $57 |
| Metronidazole | 19 | $786 | $41 |
| Betamethasone Diprop Augmented | 15 | $597 | $40 |
| Triamcinolone Acetonide | 53 | $544 | $10 |
| Doxycycline Monohydrate | 26 | $413 | $16 |
| Fluocinonide | 20 | $374 | $19 |
| Minoxidil | 28 | $347 | $12 |
| Mupirocin | 49 | $336 | $7 |
| Hydrocortisone | 41 | $137 | $3 |
| Finasteride | 15 | $132 | $9 |
| Hydroxychloroquine Sulfate | 11 | $56 | $5 |
| Terbinafine | 11 | $43 | $4 |
Year by year
| 2024 | 597 | 218 | 0% (0) | 8% | $119,593 |
| 2023 | 409 | 176 | 0% (0) | 6% | $48,652 |
| 2022 | 238 | 116 | None | None | $8,658 |
| 2021 | 96 | 43 | None | 0% | $3,190 |
| 2020 | 104 | 58 | None | None | $33,880 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Clobetasol Propionate | 39 | $1,529 | $39 |
| Betamethasone Diprop Augmented | 23 | $1,444 | $63 |
| Ketoconazole | 45 | $1,105 | $25 |
| Fluorouracil | 14 | $975 | $70 |
| Betamethasone Dipropionate | 12 | $801 | $67 |
| Fluocinonide | 21 | $798 | $38 |
| Metronidazole | 11 | $626 | $57 |
| Triamcinolone Acetonide | 36 | $317 | $9 |
| Doxycycline Monohydrate | 20 | $238 | $12 |
| Mupirocin | 26 | $211 | $8 |
| Hydrocortisone | 28 | $123 | $4 |
| Finasteride | 11 | $121 | $11 |
2022: 8 drugs
| Doxycycline Hyclate | 18 | $1,391 | $77 |
| Clobetasol Propionate | 16 | $1,216 | $76 |
| Fluorouracil | 15 | $976 | $65 |
| Triamcinolone Acetonide | 32 | $688 | $21 |
| Ketoconazole | 30 | $631 | $21 |
| Metronidazole | 11 | $564 | $51 |
| Fluocinonide | 11 | $493 | $45 |
| Minoxidil | 11 | $91 | $8 |
2021: 1 drug
| Ketoconazole | 15 | $295 | $20 |
2020: 2 drugs
| Triamcinolone Acetonide | 19 | $367 | $19 |
| Ketoconazole | 11 | $263 | $24 |
Money from drug and device companies
$2,732 in 2025
| 2025 | 16 | 94 | None | $2,732 |
| 2024 | 5 | 5 | None | $138 |
| 2023 | 2 | 2 | None | $52 |
| 2022 | 1 | 1 | None | $185 |
| 2021 | 2 | 5 | None | $158 |
| 2020 | 2 | 8 | None | $419 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $529 | 18 payments
|
| Galderma Laboratories L.P. | Nemluvio | $462 | 11 payments
|
| Incyte | Opzelura | $374 | 6 payments
|
| Lilly USA | Taltz | $252 | 10 payments
|
| Arcutis Biotherapeutics | Zoryve | $228 | 14 payments
|
| Genzyme | Dupixent | $205 | 8 payments
|
See all 94 published payments
| Arcutis Biotherapeutics | Meals · 2025-12-22 | Zoryve | $26 |
| Incyte | Meals · 2025-12-19 | Opzelura | $28 |
| Abbvie | Meals · 2025-12-17 | Skyrizi | $12 |
| Revance Therapeutics | Meals · 2025-12-16 | Daxi | $26 |
| Abbvie | Meals · 2025-12-12 | Rinvoq | $25 |
| Genzyme | Meals · 2025-12-12 | Dupixent | $26 |
| Abbvie | Meals · 2025-12-06 | Skyrizi | $19 |
| Arcutis Biotherapeutics | Meals · 2025-12-03 | Zoryve | $25 |
| Ucb | Meals · 2025-11-21 | Bimzelx | $27 |
| Pfizer | Meals · 2025-11-18 | Cibinqo | $20 |
| Arcutis Biotherapeutics | Meals · 2025-11-18 | Zoryve | $13 |
| Genzyme | Meals · 2025-11-14 | Dupixent | $25 |
| Abbvie | Meals · 2025-11-12 | Skyrizi | $28 |
| Novartis Pharmaceuticals | Meals · 2025-11-07 | Cosentyx | $22 |
| Abbvie | Meals · 2025-11-04 | Rinvoq | $20 |
| Arcutis Biotherapeutics | Meals · 2025-10-30 | Zoryve | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-10-28 | Dupixent | $28 |
| Galderma Laboratories L.P. | Meals · 2025-10-24 | Nemluvio | $14 |
| Abbvie | Meals · 2025-10-23 | Skyrizi | $32 |
| Galderma Laboratories L.P. | Meals · 2025-10-23 | Nemluvio | $19 |
| Abbvie | Meals · 2025-10-21 | Rinvoq | $128 |
| Incyte | Meals · 2025-10-16 | Opzelura | $30 |
| Lilly USA | Meals · 2025-10-14 | Taltz | $32 |
| Incyte | Meals · 2025-10-10 | Opzelura | $29 |
| Galderma Laboratories L.P. | Meals · 2025-10-10 | Nemluvio | $16 |
| Incyte | Meals · 2025-10-08 | Opzelura | $128 |
| Organon | Meals · 2025-10-07 | Vtama | $31 |
| Sun Pharmaceutical Industries | Meals · 2025-09-30 | Ilumya | $30 |
| Genzyme | Meals · 2025-09-26 | Dupixent | $36 |
| Abbvie | Meals · 2025-09-25 | Skyrizi | $29 |
| Galderma Laboratories L.P. | Meals · 2025-09-24 | Nemluvio | $11 |
| Galderma Laboratories L.P. | Meals · 2025-09-23 | Nemluvio | $14 |
| Lilly USA | Meals · 2025-09-11 | Taltz | $28 |
| Abbvie | Meals · 2025-09-05 | Rinvoq | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-09-04 | Dupixent | $28 |
| Arcutis Biotherapeutics | Meals · 2025-08-22 | Zoryve | $6 |
| Merz North America | Meals · 2025-08-21 | None | $33 |
| Galderma Laboratories L.P. | Meals · 2025-08-19 | None | $170 |
| Incyte | Meals · 2025-08-15 | Opzelura | $131 |
| Lilly USA | Meals · 2025-08-14 | Taltz | $29 |
| Abbvie | Meals · 2025-08-12 | Skyrizi | $11 |
| Revance Therapeutics | Meals · 2025-08-04 | None | $21 |
| Abbvie | Meals · 2025-08-01 | Rinvoq | $30 |
| Galderma Laboratories L.P. | Meals · 2025-08-01 | Nemluvio | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-07-22 | Dupixent | $29 |
| Ucb | Meals · 2025-07-15 | Bimzelx | $27 |
| Arcutis Biotherapeutics | Meals · 2025-07-11 | Zoryve | $29 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $31 |
| Genzyme | Meals · 2025-06-20 | Dupixent | $37 |
| Lilly USA | Meals · 2025-06-06 | Taltz | $30 |
| Pfizer | Meals · 2025-06-05 | Cibinqo | $26 |
| Lilly USA | Meals · 2025-05-29 | Ebglyss | $24 |
| Lilly USA | Meals · 2025-05-29 | Ebglyss | $2 |
| Pfizer | Meals · 2025-05-29 | Cibinqo | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Dupixent | $34 |
| Galderma Laboratories L.P. | Meals · 2025-05-27 | Nemluvio | $129 |
| Arcutis Biotherapeutics | Meals · 2025-05-23 | Zoryve | $6 |
| Revance Therapeutics | Meals · 2025-05-22 | None | $13 |
| Galderma Laboratories L.P. | Meals · 2025-05-19 | None | $22 |
| Arcutis Biotherapeutics | Meals · 2025-05-18 | Zoryve | $5 |
| Abbvie | Meals · 2025-05-16 | Skyrizi | $16 |
| Lilly USA | Meals · 2025-05-09 | Taltz | $30 |
| Arcutis Biotherapeutics | Meals · 2025-05-08 | Zoryve | $22 |
| Ucb | Meals · 2025-05-07 | Bimzelx | $23 |
| Genzyme | Meals · 2025-05-06 | Dupixent | $38 |
| Lilly USA | Meals · 2025-05-02 | Taltz | $29 |
| Revance Therapeutics | Meals · 2025-05-01 | Daxi | $22 |
| Incyte | Meals · 2025-04-29 | Opzelura | $28 |
| Lilly USA | Meals · 2025-04-27 | Taltz | $22 |
| LEO Pharma | Meals · 2025-04-25 | Adbry | $21 |
| Arcutis Biotherapeutics | Meals · 2025-04-24 | Zoryve | $12 |
| Genzyme | Meals · 2025-04-22 | Dupixent | $14 |
| Galderma Laboratories L.P. | Meals · 2025-04-17 | Nemluvio | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-04-15 | Dupixent | $29 |
| Ucb | Meals · 2025-04-04 | Bimzelx | $29 |
| Arcutis Biotherapeutics | Meals · 2025-04-03 | Zoryve | $4 |
| Galderma Laboratories L.P. | Meals · 2025-04-01 | Nemluvio | $15 |
| Abbvie | Meals · 2025-03-26 | Rinvoq | $27 |
| LEO Pharma | Meals · 2025-03-18 | Adbry | $25 |
| Abbvie | Meals · 2025-03-12 | Skyrizi | $15 |
| Genzyme | Meals · 2025-03-11 | Dupixent | $11 |
| Abbvie | Meals · 2025-03-08 | Skyrizi | $16 |
| Arcutis Biotherapeutics | Meals · 2025-03-04 | Zoryve | $10 |
| Abbvie | Meals · 2025-02-28 | Rinvoq | $31 |
| Surgenex | Meals · 2025-02-25 | Surgraft | $30 |
| Arcutis Biotherapeutics | Meals · 2025-02-18 | Zoryve | $24 |
| Genzyme | Meals · 2025-02-11 | Dupixent | $18 |
| Lilly USA | Meals · 2025-02-06 | Ebglyss | $27 |
| LEO Pharma | Meals · 2025-01-31 | Adbry | $19 |
| Ucb | Meals · 2025-01-30 | Bimzelx | $14 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | Cosentyx | $29 |
| Abbvie | Meals · 2025-01-25 | Rinvoq | $28 |
| Arcutis Biotherapeutics | Meals · 2025-01-24 | Zoryve | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-01-17 | Dupixent | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $138
| Abbvie | Rinvoq | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $29 | 1 payment
|
| Ucb | Bimzelx | $29 | 1 payment
|
| Dermavant Sciences | Vtama | $27 | 1 payment
|
| Incyte | Opzelura | $22 | 1 payment
|
2023: $52
| Regeneron Healthcare Solutions | Dupixent | $36 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $185
| Allergan | Natrelle Saline-Filled Breast Implants | $185 | 1 payment
|
2021: $158
| AbbVie | Skyrizi | $144 | 4 payments
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $14 | 1 payment
|
2020: $419
| AbbVie | Skyrizi | $279 | 6 payments
|
| Regeneron Healthcare Solutions | Dupixent | $140 | 2 payments
|
Professional record
- NPI
- 1043695174
- Licence
- CA A164401California A164401: Current · expires 2027-08-31
- Trained
- University of California, Davis School of Medicine, 2018
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 280 Baldwin Ave, San Mateo, CA, 94401
- NPI first listed
- 2015-07-30
- NPI last updated
- 2024-10-06
- NPI record certified
- 2024-10-06
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2490 Hospital Dr Ste 201, Mountain View, CA, 94040